

Monthly Market Commentary

Global equity markets delivered mixed returns in the first quarter of 2026. The period was defined by a sharp market shift. A supportive backdrop in January and February, characterised by falling yields and improving leading indicators, gave way to a more uncertain environment as geopolitical tensions escalated with the onset of war in Iran.

The market narrative flipped quickly. Early in the quarter, easing financial conditions and improving growth data supported a rotation away from the most crowded areas of the market, with signs of cyclical broadening. The AI complex began to face greater scrutiny, weighing on large cap technology stocks. This dynamic shifted in March as oil prices surged, at one point nearly doubling year to date, and appeared to dictate market direction. Equities traded increasingly with a negative correlation with crude, while inflation concerns resurfaced and expectations for monetary easing gave way to a more uncertain policy outlook.

By region, the US lagged in both relative and absolute terms, with the S&P 500 down 2.4% and the NASDAQ falling 4.7%, reflecting weakness in large-cap technology and software as the AI trade came under scrutiny. In Asia, Japan outperformed, rising 13.6%, while China was largely unchanged, with the Shanghai Composite up just 0.2%. Europe gained 4.5% overall despite a sharp drawdown in March. Within the region, the UK was the standout, with the FTSE 100 up 8.8%, while Germany lagged. The DAX fell 5%, as its more energy intensive industrial base proved particularly exposed to the rise in oil prices.

Against this backdrop the Fund delivered a return of +0.37% for the quarter.

Distributions: The Fund paid a March 2026 quarterly distribution of 7.25 cents per unit taking its 12-month income return to +8.66.

Within sectors, leadership reversed. The best performers of the past three years lagged, while prior laggards outperformed. Energy was the clear standout, rising 37.6% as the blockage of the Strait of Hormuz tightened supply and lifted oil prices. Materials followed, up 12.8%, supported by strength in gold and silver. By contrast, Consumer Discretionary and Technology were the weakest sectors, down 10.4% and 8.0% respectively. Software stocks in particular came under pressure as concerns grew around AI disruption to existing business models, alongside broader scrutiny of the sector.

The price of oil surged 76%, closing the quarter at over \$100 a barrel for the first time since 2022 on the back of the conflict in the Middle East. The Bloomberg Commodity basket was also up strongly at +23.3% for the quarter. Fears of an inflation shock pushed bond yields higher, the US 10 year closed the quarter at 4.32%, up 15 bps since the start of January and up as much as 40bps from the lows in late February. The VIX was up by over 10 points, closing the quarter at 25.3, the highest since April of last year.

Looking at the portfolio, the biggest contributor to performance was EOG, an oil and gas producer in the US that benefits from rising oil prices. We have used this strength to sell call options on a portion of the position. CF Industries, a US based maker of fertiliser, was another strong contributor to performance. Gas supply disruption from the Middle East directly impacts its main competitors in Europe and Asia. We have exited the shares after they exceeded our assessment of fair value.

The main detractors from portfolio performance were Essity and HP. Essity underperformed in AUD terms both because of a weak Swedish Kroner and because of negative implications for profit margins from the spike in energy costs. HP's underperformance was driven by a big increase in the price of memory chips, a key input for their computer business. We continue to hold both shares.

During the quarter, the Fund initiated new positions in Exor (see Stock in Focus) and a very modest position in Adobe. Exor, a holding company for the Agnelli family, currently trades at over a 50% discount to Net Asset Value (NAV), despite per share compounding at ~18% per annum since 2009.

The Fund exited Johnson & Johnson, CF Industries and Canadian Utilities on valuation grounds following strong prior performance for all three.

We believe the most compelling way to compound clients' wealth is by utilising multiple return sources to deliver superior risk-adjusted investment outcomes.

- Long-term compounding of investor wealth
- Multiple sources of return
- Quarterly distributions
- Risk focused investment mindset



The investment process behind the Talaria Global Equity Fund Complex ETF takes a high conviction, value biased approach to construct a portfolio of high quality, large cap companies from around the globe. Our unique investment methodology harnesses the benefits of consistent income generation and capital appreciation to grow investors' real wealth.

Performance as at 31 March 2026¹

	1 Month	3 Months	6 Months	1 Year	3 Years (pa)	5 Years (pa)	7 Years (pa)	10 Years (pa)	Since Inception (pa) ²
Total Return	1.45%	0.37%	2.56%	2.60%	7.17%	9.69%	8.78%	8.81%	7.33%
Avg. Market Exposure⁴	55%	54%	56%	58%	60%	58%	58%	59%	61%

¹ Fund Returns are calculated after fees and expenses and assume the reinvestment of distributions.
² Inception date for performance calculation is 18 August 2008.
³ Past performance is not a reliable indicator of future performance.


⁴ Average Market Exposure calculated on delta-adjusted exposure of underlying portfolio. Since inception market exposure is calculated from September 2008.

Growth of \$10,000 Since Inception⁵



⁵ Calculations are based on exit price, net of management fees and expenses and assumes reinvestment of distributions Past performance is not a reliable indicator of future performance.

Annual Distributions⁶




⁶ Illustrates Distribution Returns for the Talaria Global Equity Fund Complex ETF Units for the financial year ending 30 June 2025. Inception date is 18 August 2008.

Top 10 Holdings⁷

Company Name	Holding	Country	Sector	Description
Roche	5.2%	Switzerland	Health Care	A global leader in cancer treatments
Newmont	4.6%	USA	Materials	One of the top 3 gold producers in the world
GSK	4.6%	United Kingdom	Health Care	One of the world's largest pharmaceutical companies.
Exor	4.5%	Netherlands	Financials	A diversified holding company
Everest Group	4.5%	USA	Financials	Leading global provider of reinsurance and insurance services
Bunzl	4.2%	United Kingdom	Industrials	Multinational distribution and outsourcing business
Bayer	4.2%	Germany	Health Care	Multinational pharmaceutical and life sciences company
EOG Resources	4.0%	USA	Energy	One of North America's largest independent oil and gas producers
Henkel	3.9%	Germany	Consumer Staples	A multinational household products and adhesives company
A.O Smith	3.8%	USA	Industrials	A leading manufacturer of water heaters in North America


⁷ Weightings include option positions held and cash backing put options. It assumes that put options will be exercised. Should the put option not be exercised the cash will revert to the unencumbered cash portfolio or may be used to cover further put options.

Sector Allocation⁸



^{8,9} Weightings include option positions held and cash backing put options. It assumes that put option will be exercised. Should the put option not be exercised the cash will revert to the unencumbered cash portfolio or may be used to cover further put options.

Regional Allocation⁹



* USA includes American Depository Receipts (ADRs) listings.

Fund Snapshot

APIR Code	AUS0035AU	Inception Date	18 August 2008
Management Fee	1.16% p.a. of the net asset value of the Fund plus Recoverable Expenses	Liquidity	Daily
Recoverable Expenses	Estimated to be 0.12% of net asset value of the Fund each Financial Year	Exit Price	\$4.90390 (31 Mar 2026)
Major Platform Availability	Asgard, Ausmaq, BT Panorama, BT Wrap, CFS Edge, CFS FirstChoice, Dash, Expand, Hub24, IconIQ, IOOF Pursuit, Linear, Macquarie, Mason Stevens, Netwealth, North, Powerwrap, Praemium	Buy / Sell Spread	0.20% / 0.20%
		Distributions	Quarterly
		Minimum Investment	\$5,000

Important Information

Equity Trustees Limited ("Equity Trustees") (ABN 46 004 031 298), AFSL 240975, is the Responsible Entity for the Talaria Global Equity Fund Complex ETF ("the Fund"). Equity Trustees is a subsidiary of EQT Holdings Limited (ABN 22 607 797 615), a publicly listed company on the Australian Securities Exchange (ASX: EQT). This report has been prepared by Talaria Asset Management (Talaria) to provide you with general information only. In preparing this information, we did not take into account the investment objectives, financial situation or particular needs of any particular person. It is not intended to take the place of professional advice and you should not take action on specific issues in reliance on this information. Neither Talaria, Equity Trustees nor any of its related parties, their employees or directors, provide any warranty of accuracy or reliability in relation to such information or accepts any liability to any person who relies on it. Past performance should not be taken as an indicator of future performance. You should obtain a copy of the Product Disclosure Statement before making a decision about whether to invest in this product. Talaria Global Equity Fund Complex ETF's Target Market Determination is available here. A Target Market Determination is a document which is required to be made available from 5 October 2021. It describes who this financial product is likely to be appropriate for (i.e. the target market), and any conditions around how the product can be distributed to investors. It also describes the events or circumstances where the Target Market Determination for this financial product may need to be reviewed. The Zenith Investment Partners (ABN 27 103 132 672, AFS Licence 226872) ("Zenith") rating (assigned November 2025 for fund AUS0035AU) referred to in this piece is limited to "General Advice" (s766B Corporations Act 2001) for Wholesale clients only. This advice has been prepared without taking into account the objectives, financial situation or needs of any individual, including target markets of financial products, where applicable, and is subject to change at any time without prior notice. It is not a specific recommendation to purchase, sell or hold the relevant product(s). Investors should seek independent financial advice before making an investment decision and should consider the appropriateness of this advice in light of their own objectives, financial situation and needs. Investors should obtain a copy of, and consider the PDS or offer document before making any decision and refer to the full Zenith Product Assessment available on the Zenith website. Past performance is not an indication of future performance. Zenith usually charges the product issuer, fund manager or related party to conduct Product Assessments. Full details regarding Zenith's methodology, ratings definitions and regulatory compliance are available on our Product Assessments and at Fund Research Regulatory Guidelines. The rating issued 04/2025 is published by Lonsac Research Pty Ltd ABN 11 151 658 561 AFSL 421 445 (Lonsac). Ratings are general advice only, and have been prepared without taking account of your objectives, financial situation or needs. Consider your personal circumstances, read the product disclosure statement and seek independent financial advice before investing. The rating is not a recommendation to purchase, sell or hold any product. Past performance information is not indicative of future performance. Ratings are subject to change without notice and Lonsac assumes no obligation to update. Lonsac uses objective criteria and receives a fee from the Fund Manager. Visit lonsac.com.au for ratings information and to access the full report. © 2025 Lonsac. All rights reserved. The Genium rating (assigned May 2025) presented in this document is issued by Genium Investment Partners Pty Ltd ABN 15 165 099 785, which is a Corporate Authorised Representative of Genium Advisory Services Pty Ltd ABN 94 304 403 582, AFSL 246580. The Rating is limited to "General Advice" (s766B Corporations Act 2001 (Cth)) and has been prepared without taking into account the objectives, financial situation or needs of any individual, including target markets of financial products, where applicable, and is subject to change at any time without notice. Past performance information is for illustrative purposes only and is not indicative of future performance. It is not a recommendation to purchase, sell or hold the relevant product(s). Investors should seek independent financial advice before making an investment decision in relation to this financial product(s). Genium receives a fee from the Fund Manager for researching and rating the product(s). Visit genium.com.au for information regarding Genium's Ratings methodology. The Global Industry Classification Standard ("GICS") was developed by and is the exclusive property and a service mark of MSCI Inc. ("MSCI") and Standard & Poor's, a division of The McGraw-Hill Companies, Inc. ("S&P") and is licensed for use by Talaria Asset Management. Neither MSCI, S&P nor any third party involved in making or compiling the GICS or any GICS classifications makes any express or implied warranties or representations with respect to such standard or classification (or the results to be obtained by the use thereof), and all such parties hereby expressly disclaim all warranties of originality, accuracy, completeness, merchantability and fitness for a particular purpose with respect to any of such standard or classification. Without limiting any of the foregoing, in no event shall MSCI, S&P, any of their affiliates or any third party involved in making or compiling the GICS or any GICS classifications have any liability for any direct, indirect, special, punitive, consequential or any other damages (including lost profits) even if notified of the possibility of such damages.

